Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 7 de 7
1.
Int J Mol Sci ; 23(3)2022 Jan 19.
Article En | MEDLINE | ID: mdl-35163014

The human organic cation transporter 2 (hOCT2) mediates renal and neuronal cellular cisplatin and oxaliplatin uptake, and therefore plays a significant role in the development of side effects associated with these chemotherapeutic drugs. Autophagy is induced by cisplatin and oxaliplatin treatment and is believed to promote cell survival under stressful conditions. We examined in vitro the role of hOCT2 on autophagy induced by cisplatin and oxaliplatin. We also explored the effect of autophagy on toxicities of these platinum derivatives. Our results indicate that autophagy, measured as LC3 II accumulation and reduction in p62 expression level, is induced in response to cisplatin and oxaliplatin in HEK293-hOCT2 but not in wild-type HEK293 cells. Furthermore, inhibition of autophagy is associated with higher toxicity of platinum derivatives, and starvation was found to offer protection against cisplatin-associated toxicity. In conclusion, activation of autophagy could be a potential strategy to protect against unwanted toxicities induced by treatment with platinum derivatives.


Microtubule-Associated Proteins/metabolism , Organic Cation Transporter 2/genetics , Platinum/toxicity , Sequestosome-1 Protein/metabolism , Autophagy , Biomarkers/metabolism , Cisplatin/toxicity , Gene Expression Regulation/drug effects , HEK293 Cells , Humans , Mutation , Oxaliplatin/toxicity
2.
Int J Mol Sci ; 21(14)2020 Jul 21.
Article En | MEDLINE | ID: mdl-32708212

Vectorial transport of organic cations (OCs) in renal proximal tubules is mediated by sequential action of human OC transporter 2 (hOCT2) and human multidrug and toxic extrusion protein 1 and 2K (hMATE1 and hMATE2K), expressed in the basolateral (hOCT2) and luminal (hMATE1 and hMATE2K) plasma membranes, respectively. It is well known that hOCT2 activity is subjected to rapid regulation by several signaling pathways, suggesting that renal OC secretion may be acutely adapted to physiological requirements. Therefore, in this work, the acute regulation of hMATEs stably expressed in human embryonic kidney cells was characterized using the fluorescent substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP+) as a marker. A specific regulation of ASP+ transport by hMATE1 and hMATE2K measured in uptake and efflux configurations was observed. In the example of hMATE1 efflux reduction by inhibition of casein kinase II, it was also shown that this regulation is able to modify transcellular transport of ASP+ in Madin-Darby canine kidney II cells expressing hOCT2 and hMATE1 on the basolateral and apical membrane domains, respectively. The activity of hMATEs can be rapidly regulated by some intracellular pathways, which sometimes are common to those found for hOCTs. Interference with these pathways may be important to regulate renal secretion of OCs.


Biological Transport/drug effects , Cations/metabolism , Cimetidine/pharmacology , Organic Cation Transport Proteins/metabolism , Animals , Biological Transport/genetics , Casein Kinase II/antagonists & inhibitors , Dogs , Fluorescence , Fluorescent Dyes/metabolism , Guanidines/pharmacology , HEK293 Cells , Humans , Kidney/metabolism , Madin Darby Canine Kidney Cells , Organic Cation Transport Proteins/antagonists & inhibitors , Organic Cation Transport Proteins/genetics , Pyridinium Compounds/metabolism , Sodium-Hydrogen Exchanger 1/antagonists & inhibitors , Sulfones/pharmacology
3.
J Clin Pharmacol ; 60(8): 1076-1086, 2020 08.
Article En | MEDLINE | ID: mdl-32149389

Gabapentin (GBP) is an organic cation mainly eliminated unchanged in urine, and active drug secretion has been suggested to contribute to its renal excretion. Our objective was to evaluate the potential drug-drug interaction between GBP and cetirizine (CTZ), an inhibitor of transporters for organic cations. An open-label, 2-period, crossover, nonrandomized clinical trial was conducted in patients with neuropathic pain to evaluate the effect of CTZ on GBP pharmacokinetics. Twelve participants were treated with a single dose of 300 mg GBP (treatment A) or with 20 mg/d of CTZ for 5 days and 300 mg GBP on the last day of CTZ treatment (treatment B). Blood sampling and pain intensity evaluation were performed up to 36 hours after GBP administration. The interaction of GBP and CTZ with transporters for organic cations was studied in human embryonic kidney (HEK) cells expressing the organic cation transporters (OCTs), multidrug and toxin extrusion proteins (MATEs), and OCTN1. CTZ treatment resulted in reduced area under the concentration-time curve and peak concentration compared with treatment A. In treatment B, the lower plasma concentrations of GBP resulted in reduced pain attenuation. GBP renal clearance was similar between treatments. GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells. At therapeutic concentrations, CTZ interacts with hMATE1 and OCTN1. In summary, CTZ reduced the systemic exposure to GBP and its effect on neuropathic pain attenuation. However, CTZ × GBP interaction is not mediated by the renal transporters.


Analgesics/pharmacokinetics , Cetirizine/metabolism , Cetirizine/pharmacokinetics , Gabapentin/pharmacokinetics , Organic Cation Transport Proteins/metabolism , Adult , Analgesics/administration & dosage , Analgesics/blood , Analgesics/urine , Area Under Curve , Cations/metabolism , Cetirizine/administration & dosage , Cross-Over Studies , Drug Interactions , Female , Gabapentin/administration & dosage , Gabapentin/blood , Gabapentin/urine , HEK293 Cells , Humans , Male , Middle Aged , Neuralgia/drug therapy , Organic Cation Transport Proteins/genetics , Organic Cation Transporter 2/genetics , Pain Measurement/drug effects , Polymorphism, Genetic , Renal Elimination/drug effects , Symporters/genetics , Symporters/metabolism
4.
J Pharm Biomed Anal ; 184: 113172, 2020 May 30.
Article En | MEDLINE | ID: mdl-32109709

A high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was successfully developed for the simultaneous detection of gabapentin (GBP) and cetirizine (CTZ) in cell lysates. Multiple reaction monitoring (MRM) transitions were found for GBP, CTZ and deuterated internal standards of both, allowing a selective and sensitive detection. Limits of detection (LODs) of 0.04 ng/mL and 0.07 ng/mL were achieved for CTZ and GBP respectively, and a linear range could be confirmed to the highest tested concentration of 50 ng/mL. Furthermore, with a total runtime of 2.5 min, this method allows a high throughput analysis. The applicability of the method was demonstrated by using it for the quantification of CTZ and GBP in cell lysates to examine the effects of renal transporters on these two analytes.


Cetirizine/chemistry , Chromatography, High Pressure Liquid/methods , Gabapentin/chemistry , Tandem Mass Spectrometry/methods , Limit of Detection , Reproducibility of Results
5.
Arch Toxicol ; 93(10): 2835-2848, 2019 10.
Article En | MEDLINE | ID: mdl-31493026

Cisplatin (CDDP) is one of the most important chemotherapeutic drugs in modern oncology. However, its use is limited by severe toxicities, which impair life quality after cancer. Here, we investigated the role of organic cation transporters (OCT) in mediating toxicities associated with chronic (twice the week for 4 weeks) low-dose (4 mg/kg body weight) CDDP treatment (resembling therapeutic protocols in patients) of wild-type (WT) mice and mice with OCT genetic deletion (OCT1/2-/-). Functional and molecular analysis showed that OCT1/2-/- mice are partially protected from CDDP-induced nephrotoxicity and peripheral neurotoxicity, whereas ototoxicity was not detectable. Surprisingly, proteomic analysis of the kidneys demonstrated that genetic deletion of OCT1/2 itself was associated with significant changes in expression of proinflammatory and profibrotic proteins which are part of an OCT-associated protein network. This signature directly regulated by OCT consisted of three classes of proteins, viz., profibrotic proteins, proinflammatory proteins, and nutrient sensing molecules. Consistent with functional protection, CDDP-induced proteome changes were more severe in WT mice than in OCT1/2-/- mice. Laser ablation-inductively coupled plasma-mass spectrometry analysis demonstrated that the presence of OCT was not associated with higher renal platinum concentrations. Taken together, these results redefine the role of OCT from passive membrane transporters to active modulators of cell signaling in the kidney.


Antineoplastic Agents/toxicity , Cisplatin/toxicity , Octamer Transcription Factor-1/genetics , Organic Cation Transporter 2/genetics , Animals , Antineoplastic Agents/administration & dosage , Cisplatin/administration & dosage , Kidney Diseases/chemically induced , Kidney Diseases/genetics , Kidney Diseases/pathology , Male , Mice , Mice, Knockout , Neurotoxicity Syndromes/etiology , Neurotoxicity Syndromes/genetics , Octamer Transcription Factor-1/metabolism , Organic Cation Transporter 2/metabolism , Ototoxicity/etiology , Ototoxicity/genetics , Proteomics , Signal Transduction/drug effects
6.
SLAS Discov ; 24(9): 904-914, 2019 10.
Article En | MEDLINE | ID: mdl-31318583

Organic cation transporters (OCTs) are membrane proteins with relevant physiological (because they accept neurotransmitters as substrate) and pharmacological (because of their interaction with drugs) roles. The human OCTs hOCT1 (SLC22A1/hOCT1) and hOCT2 (SLC22A2/hOCT2) are highly expressed in hepatic (hOCT1) and in renal and neuronal tissue (hOCT2), suggesting a possible role in modulating neurotransmitter activity in the liver, kidney, and brain, and their clearance from the blood. Even though there are several data demonstrating that OCTs are regulated under various patho-physiological conditions, it remains largely unknown which proteins directly interact with OCTs and thereby influence their cellular processing, localization, and function. In this work, using a mating-based split-ubiquitin yeast two-hybrid system, we characterized the potential interactome of hOCT1 and 2. It became evident that these OCTs share some potential interaction partners, such as the tetraspanins CD63 and CD9. Moreover, we confirmed interaction of hOCT2 with CD9 by fluorescence-activated cell sorting coupled with Förster resonance energy transfer analysis. Together with other proteins, tetraspanins build "tetraspanins webs" in the plasma membrane, which are able to regulate cellular trafficking and compartmentalization of interacting partners. While CD63 was demonstrated to mediate the localization of the hOCT2 to the endosomal system, we show here that co-expression of hOCT2 and CD9 led to strong cell surface localization of the transporter. These data suggest that tetraspanins regulate the cellular localization and function of OCTs. Co-localization of CD9 and hOCT was confirmed in tissues endogenously expressing proteins, highlighting the potential biological relevance of this interaction.


Octamer Transcription Factor-1/metabolism , Organic Cation Transporter 2/metabolism , Tetraspanin 29/metabolism , Tetraspanins/metabolism , Animals , Cell Membrane/metabolism , Dogs , HEK293 Cells , Humans , Madin Darby Canine Kidney Cells , Membrane Proteins/metabolism , Protein Transport/physiology
7.
J Invest Dermatol ; 139(2): 439-447, 2019 02.
Article En | MEDLINE | ID: mdl-30273596

Tyrosine kinase inhibitors have emerged as a therapeutic option for rheumatic diseases such as systemic sclerosis (SSc). Because tyrosine kinases like c-Abl kinase are important for fibroblast activation and fibrosis development in SSc, the c-Abl inhibitor imatinib was proposed for SSc treatment. Transporters for organic cations have become increasingly recognized as an important determinant for uptake and efficacy of tyrosine kinase inhibitors. Therefore, we investigated the role of organic cation transporters in the uptake of imatinib. Moreover, the influence of important SSc pathogenetic factors, like PDGF and Notch pathway activation on these uptake processes, has been studied. We showed that organic cation transporters OCT1-3, novel organic cation transporters OCTN1/2, and the multidrug and toxin extrusion protein MATE1 are expressed in healthy dermal and SSc fibroblasts. Decreased expression levels of MATE1 and decreased imatinib uptake were measured in SSc fibroblasts. In small interfering RNA experiments, MATE1 was identified as key transporter for imatinib uptake and biological effect in dermal fibroblasts. Furthermore, PDGF reduced imatinib uptake by decreasing MATE1 expression in SSc fibroblasts, but not in healthy fibroblasts. Blocking the Notch pathway in SSc fibroblasts increased MATE1 transporter expression and imatinib uptake. In conclusion, MATE1-mediated transport governs therapeutic efficacy of imatinib in SSc.


Imatinib Mesylate/pharmacokinetics , Organic Cation Transport Proteins/metabolism , Protein Kinase Inhibitors/pharmacokinetics , Receptors, Notch/metabolism , Scleroderma, Systemic/drug therapy , Biopsy , Cells, Cultured , Dermis/cytology , Dermis/metabolism , Dermis/pathology , Fibroblasts/metabolism , Gene Knockdown Techniques , Humans , Imatinib Mesylate/therapeutic use , Organic Cation Transport Proteins/genetics , Platelet-Derived Growth Factor/metabolism , Primary Cell Culture , Protein Kinase Inhibitors/therapeutic use , RNA, Small Interfering/metabolism , Scleroderma, Systemic/pathology , Signal Transduction
...